Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Annals of the Rheumatic Diseases Année : 2018

Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency

Gillian Rice
  • Fonction : Auteur
  • PersonId : 932509
Darragh Duffy

Résumé

The type I interferonopathies, Mendelian disorders characterised by constitutive upregulation of the type I interferon (IFN) pathway, are associated with a spectrum of phenotypes particularly involving the brain and the skin.1 Mutations in the 3′−5′ DNA exonuclease TREX1 were the first described cause of the severe encephalopathy Aicardi-Goutières syndrome (AGS),2 of which acral vasculitic lesions are a well-recognised feature [...]

Domaines

Immunologie

Dates et versions

pasteur-01962416 , version 1 (20-12-2018)

Identifiants

Citer

Coralie Briand, Marie-Louise Frémond, Didier Bessis, Aurélia Carbasse, Gillian Rice, et al.. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Annals of the Rheumatic Diseases, 2018, pp.annrheumdis-2018-214037. ⟨10.1136/annrheumdis-2018-214037⟩. ⟨pasteur-01962416⟩
40 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More